Frankfurt - Delayed Quote EUR

Ascendis Pharma A/S (A71.F)

Compare
119.00
-2.00
(-1.65%)
As of 8:01:28 AM GMT+1. Market Open.
Currency in EUR All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
327,427.00
266,718.00
51,174.00
7,778.00
6,953.00
Cost of Revenue
49,692.00
44,395.00
12,137.00
3,523.00
--
Gross Profit
277,735.00
222,323.00
39,037.00
4,255.00
6,953.00
Operating Expense
593,492.00
677,864.00
600,851.00
456,047.00
337,573.00
Operating Income
-315,757.00
-455,541.00
-561,814.00
-451,792.00
-330,620.00
Net Non Operating Interest Income Expense
-109,779.00
-27,208.00
-23,256.00
-3,219.00
-106.00
Other Income Expense
8,591.00
8,605.00
7,253.00
71,067.00
-88,448.00
Pretax Income
-416,945.00
-474,144.00
-577,817.00
-383,944.00
-419,174.00
Tax Provision
9,548.00
7,303.00
5,377.00
-367.00
-219.00
Net Income Common Stockholders
-426,493.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Diluted NI Available to Com Stockholders
-426,493.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Basic EPS
-7.46
-8.55
-10.40
-7.00
-8.28
Diluted EPS
-7.46
-8.55
-10.40
-7.00
-8.28
Basic Average Shares
57,082.67
56,287.06
56,071.79
54,771.76
50,616.53
Diluted Average Shares
57,082.67
56,287.06
56,071.79
54,771.76
50,616.53
Total Operating Income as Reported
-315,757.00
-455,541.00
-561,814.00
-451,792.00
-330,620.00
Total Expenses
643,184.00
722,259.00
612,988.00
459,570.00
337,573.00
Net Income from Continuing & Discontinued Operation
-426,493.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Normalized Income
-447,553.00
-508,031.20
-607,911.97
-442,543.97
-340,070.46
Interest Income
-30,866.00
16,857.00
7,426.00
692.00
1,812.00
Interest Expense
78,913.00
44,065.00
30,682.00
3,911.00
1,918.00
Net Interest Income
-109,779.00
-27,208.00
-23,256.00
-3,219.00
-106.00
EBIT
-338,032.00
-430,079.00
-547,135.00
-380,033.00
-417,256.00
EBITDA
-319,816.00
-411,168.00
-529,177.00
-364,642.00
-407,808.00
Reconciled Cost of Revenue
49,692.00
44,395.00
12,137.00
3,523.00
--
Reconciled Depreciation
18,216.00
18,911.00
17,958.00
15,391.00
9,448.00
Net Income from Continuing Operation Net Minority Interest
-426,493.00
-481,447.00
-583,194.00
-383,577.00
-418,955.00
Total Unusual Items Excluding Goodwill
27,000.00
27,000.00
24,950.00
59,026.00
-78,924.00
Total Unusual Items
27,000.00
27,000.00
24,950.00
59,026.00
-78,924.00
Normalized EBITDA
-346,816.00
-438,168.00
-554,127.00
-423,668.00
-328,884.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
5,940.00
415.80
232.04
59.03
-39.46
12/31/2020 - 2/2/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

83B.F 3SBio Inc.
0.7500
+1.35%
 
RV7.F Halozyme Therapeutics, Inc.
52.64
-0.64%
 
TRSBF 3SBio Inc.
0.8279
0.00%
 
2CL.BE BridgeBio Pharma Inc
34.63
-1.20%
 
1530.HK 3SBIO
6.210
+1.14%
 
ARGX argenx SE
648.94
-0.50%
 
IPA ImmunoPrecise Antibodies Ltd.
0.5765
-3.92%
 
VKTX Viking Therapeutics, Inc.
34.50
-1.26%
 
RXRX Recursion Pharmaceuticals, Inc.
7.33
-2.66%